摘要
肿瘤学主要的药物发现都集中在选择性分子的发展中,他们被认为在这种通过修饰一个单一的或几个密切相关的药物靶点的抗肿瘤机制中有特异的行为。然而,鸟瞰多个可用的生物数据到大部分批准的抗癌药物中,事实上,目标更多的药物具有不同的功能。在这里我们将回顾当代可用的信息在不同抗癌药物和他们潜在的活性机制的靶点。目前抗肿瘤药物的多向药理学表明肿瘤药物临床疗效只能通过多个细胞机制调制实现。
关键词: 多向药理学,酪氨酸激酶抑制剂,组蛋白去乙酰化酶抑制剂,DNA拓扑异构酶抑制剂、他莫昔芬、药物靶点,多靶点药物的合理设计。
图形摘要
Current Drug Targets
Title:Polypharmacology of Approved Anticancer Drugs
Volume: 18 Issue: 5
关键词: 多向药理学,酪氨酸激酶抑制剂,组蛋白去乙酰化酶抑制剂,DNA拓扑异构酶抑制剂、他莫昔芬、药物靶点,多靶点药物的合理设计。
摘要: The major drug discovery efforts in oncology have been concentrated on the development of selective molecules that are supposed to act specifically on one anticancer mechanism by modulating a single or several closely related drug targets. However, a bird's eye view on data from multiple available bioassays implies that most approved anticancer agents do, in fact, target many more proteins with different functions. Here we will review and systematize currently available information on the targets of several anticancer drugs along with revision of their potential mechanisms of action. Polypharmacology of the current antineoplastic agents suggests that drug clinical efficacy in oncology can be achieved only via modulation of multiple cellular mechanisms.
Export Options
About this article
Cite this article as:
Polypharmacology of Approved Anticancer Drugs, Current Drug Targets 2017; 18 (5) . https://dx.doi.org/10.2174/1389450117666160301095233
DOI https://dx.doi.org/10.2174/1389450117666160301095233 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Epigenetic Drugs for Multiple Sclerosis
Current Neuropharmacology Astrocytes: Adhesion Molecules and Immunomodulation
Current Drug Targets Amyloidogenicity and Aggregate Cytotoxicity of Human Glucagon-Like Peptide-1 (hGLP-1)
Protein & Peptide Letters Endocannabinoids and their Involvement in the Neurovascular System
Current Neurovascular Research Assessing Combinations of Cytotoxic Agents Using Leukemia Cell Lines
Current Drug Targets Meet Our Editorial Board Member
Mini-Reviews in Medicinal Chemistry Induced Adaptive Resistance to Oxidative Stress in the CNS: A Discussion on Possible Mechanisms and Their Therapeutic Potential
Current Drug Metabolism Immunotherapy for Uveal Melanoma - Current Knowledge and Perspectives
Current Medicinal Chemistry Role of ncRNAs in Development, Diagnosis and Treatment of Human Cancer
Recent Patents on Anti-Cancer Drug Discovery Drug Targeting to the Brain - A Review
Current Nanoscience Modulation of k-Ras Signaling by Natural Products
Current Medicinal Chemistry Spermine Metabolism and Anticancer Therapy
Current Cancer Drug Targets Harnessing Impaired Energy Metabolism in Cancer Cell: Small Molecule- Mediated Ways to Regulate Tumorigenesis
Anti-Cancer Agents in Medicinal Chemistry Expression, Distribution and Regulation of Phosphodiesterase 5
Current Pharmaceutical Design Recent Advancements in 1,4-Disubstituted 1H-1,2,3-Triazoles as Potential Anticancer Agents
Anti-Cancer Agents in Medicinal Chemistry Apolipoprotein E-mediated Modulation of ADAM10 in Alzheimer's Disease
Current Alzheimer Research Breaking the Barrier of Cancer Through Liposome Loaded with Phytochemicals
Current Drug Delivery Novel Chemotherapeutic Agents - The Contribution of Scorpionates
Current Medicinal Chemistry Nonsteroidal Anti-Inflammatory Drugs in Experimental Parkinsonian Models and Parkinsons Disease
Current Pharmaceutical Design Emerging Roles of Meis1 in Cardiac Regeneration, Stem Cells and Cancer
Current Drug Targets